Quick Answer
Rapport Therapeutics, Inc. reported Operating Income of -$125.10 million for fiscal year 2025.
Rapport Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$125.10M | -50.6% |
| 2024 | -$83.06M | -129.6% |
| 2023 | -$36.18M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$29.99M | -38.6% | -1.7% |
| June 30, 2025 | -$29.50M | -41.8% | -8.8% |
| March 31, 2025 | -$27.11M | -58.6% | -25.3% |
| September 30, 2024 | -$21.64M | -126.3% | -4.0% |
| June 30, 2024 | -$20.80M | -213.7% | -21.7% |
| March 31, 2024 | -$17.09M | — | -78.7% |
| September 30, 2023 | -$9.56M | — | -44.3% |
| June 30, 2023 | -$6.63M | — | — |
- Rapport Therapeutics, Inc. showed a decrease of -50.6% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Rapport Therapeutics, Inc.’s operating income has declined by 245.8% (from -$36.18 million to -$125.10 million).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: